DPP-IV 억제제 시장

Global DPP-IV Inhibitors Market to Reach US$14.7 Billion by 2030

The global market for DPP-IV Inhibitors estimated at US$13.0 Billion in the year 2023, is expected to reach US$14.7 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 1.7% CAGR

The DPP-IV Inhibitors market in the U.S. is estimated at US$3.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 1.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

DPP-IV Inhibitors - Key Trends and Drivers

Dipeptidyl peptidase-4 (DPP-IV) inhibitors are a class of oral hypoglycemic agents used to treat type 2 diabetes mellitus. These inhibitors work by blocking the DPP-IV enzyme, which is responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1). By inhibiting this enzyme, DPP-IV inhibitors increase the levels of incretin hormones, thereby enhancing the secretion of insulin in response to meals and reducing the release of glucagon. This dual action helps to lower blood glucose levels effectively. Commonly prescribed DPP-IV inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin, which are typically used in combination with other antidiabetic medications or as monotherapy when other treatments are not suitable. These drugs have gained popularity due to their efficacy, relatively low risk of hypoglycemia, and oral administration, which is preferred by many patients over injectable therapies.

Several trends and developments are influencing the DPP-IV inhibitors market. One significant trend is the increasing prevalence of type 2 diabetes globally, driven by factors such as aging populations, sedentary lifestyles, and rising obesity rates. This surge in diabetes cases is boosting demand for effective and convenient treatment options like DPP-IV inhibitors. Additionally, ongoing research and development are leading to the introduction of new and improved DPP-IV inhibitors with enhanced efficacy and safety profiles. Pharmaceutical companies are also exploring combination therapies that pair DPP-IV inhibitors with other antidiabetic drugs, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors and metformin, to provide more comprehensive blood sugar control. Furthermore, there is a growing emphasis on personalized medicine, where treatments are tailored to individual patient profiles based on genetic, environmental, and lifestyle factors. This approach is expected to optimize the effectiveness of DPP-IV inhibitors and minimize adverse effects.

The growth in the DPP-IV inhibitors market is driven by several factors. Technological advancements in drug discovery and development are enabling the creation of more potent and selective DPP-IV inhibitors, improving patient outcomes. The rising global prevalence of type 2 diabetes particularly in emerging economies is expanding the market for these medications. Increasing awareness about diabetes management and the importance of maintaining optimal blood glucose levels is encouraging more patients to seek treatment, boosting demand for DPP-IV inhibitors. Additionally, the convenience of oral administration and the relatively favorable side effect profile of DPP-IV inhibitors are driving their adoption among patients and healthcare providers. Strategic collaborations and partnerships among pharmaceutical companies are also fostering innovation and facilitating the introduction of new products to the market. Furthermore, supportive government policies and reimbursement frameworks in many countries are making these treatments more accessible to a broader patient population, thereby driving market growth.

Select Competitors (Total 16 Featured) -

• AstraZeneca Plc.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • DPP-IV Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Type 2 Diabetes Propels Growth in DPP-IV Inhibitors Market
  • Advancements in Drug Discovery Strengthen Business Case for Enhanced DPP-IV Inhibitors
  • Rising Obesity Rates and Sedentary Lifestyles Expand Addressable Market Opportunity
  • Growing Emphasis on Personalized Medicine Drives Adoption of Tailored DPP-IV Inhibitor Therapies
  • Development of Combination Therapies Spurring Growth in Comprehensive Diabetes Management Solutions
  • Innovations in DPP-IV Inhibitors Improve Efficacy and Safety Profiles
  • Increasing Awareness about Diabetes Management Drives Demand for Effective Treatments
  • Convenience of Oral Administration Strengthens Market Position of DPP-IV Inhibitors
  • Favorable Side Effect Profile of DPP-IV Inhibitors Propels Growth among Patient Populations
  • Advances in Clinical Research Throw the Spotlight on Next-Generation DPP-IV Inhibitors
  • Lifestyle Changes and Aging Populations Drive Adoption of Diabetes Management Solutions
  • Increasing Investment in R&D Accelerates Innovation in DPP-IV Inhibitors Market
  • Integration of Digital Health Solutions Expands Addressable Market for Diabetes Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World DPP-IV Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 4: USA Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• CANADA
  • TABLE 5: Canada Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• JAPAN
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 6: Japan Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• CHINA
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 7: China Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• EUROPE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 8: Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: Europe 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
• FRANCE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 10: France Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• GERMANY
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 11: Germany Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• ITALY
  • TABLE 12: Italy Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• UNITED KINGDOM
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 13: UK Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• REST OF EUROPE
  • TABLE 14: Rest of Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• ASIA-PACIFIC
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 15: Asia-Pacific Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• REST OF WORLD
  • TABLE 16: Rest of World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR

IV. COMPETITION